Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore the effectiveness and safety of camrelizumab combined
with apatinib mesylate in the treatment of relapsed platinum-resistant epithelial ovarian
cancer